التفاصيل البيبلوغرافية
| العنوان: |
Ovarian Cancer Risk-Reduction and Screening in BRCA1/2 Mutation Carriers. |
| المؤلفون: |
DiSilvestro, Jessica B., Haddad, Jessica, Robison, Katina, Beffa, Lindsey, Laprise, Jessica, Scalia-Wilbur, Jennifer, Raker, Christina, Clark, Melissa A., Lokich, Elizabeth, Hofstatter, Erin, Dalela, Disha, Brown, Amy, Bradford, Leslie, Toland, Maris, Stuckey, Ashley |
| المصدر: |
Journal of Women's Health (15409996); May2024, Vol. 33 Issue 5, p624-628, 5p |
| مصطلحات موضوعية: |
RISK assessment, CARRIER state (Communicable diseases), CROSS-sectional method, BRCA genes, EARLY detection of cancer, OVARIAN tumors, QUESTIONNAIRES, FISHER exact test, DESCRIPTIVE statistics, ENDOSCOPIC ultrasonography, AGE distribution, EMAIL, SURVEYS, RESEARCH, ORAL contraceptives, PATIENT decision making, TUMOR antigens, GENETIC testing |
| مستخلص: |
Objective: To determine the utilization of risk-reducing strategies and screening protocols for ovarian cancer in female BRCA1/2 carriers. Methods: This study was a sub-analysis of female participants from a larger multicenter, cross-sectional survey of BRCA1/2 mutation carriers unaffected by cancer. The questionnaire was administered electronically via email at four institutions located in the northeast United States. Data were analyzed with Fisher's exact test. Results: The survey was completed by 104 female BRCA mutation carriers. BRCA subtypes included 54.3% BRCA2, 41.0% BRCA1, and 2.9% both. The age at which patients underwent genetic testing varied 21.2% were 18–24 years, 25.0% were 25–34 years, 29.8% were 35–44 years, and 24.0% were 45 years or older. Nearly, all respondents (97.1%) reported that a provider had discussed risk-reducing surgeries. Of the 79 females who underwent genetic testing before 45 years of age, 53.2% reported that a health care provider recommended taking combined oral contraceptive pills (COCs) to reduce their risk of ovarian cancer, and, of these women, 88.1% chose to use them. COCs were offered at higher rates among women who were younger at the age of genetic testing (18–24: 86%, 25–34: 62%, 35–44: 23%; p < 0.0001). Approximately half (55.8%) of the respondents reported having been offered increased screening for possible early detection of ovarian cancer, of which 81.0% chose to undergo screening. The majority utilized a combination of transvaginal ultrasound and serum CA125 measurements. There were no differences observed in screening utilization based on BRCA mutation type. Conclusion: In our cohort of female BRCA mutation carriers, risk-reducing surgery was offered to almost all women, whereas only half were offered risk-reducing medication and/or increased screening. Further investigation is needed to identify barriers to the utilization of risk-reducing strategies among this high-risk population. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Women's Health (15409996) is the property of Mary Ann Liebert, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
